Early-stage, high-innovation tech development to create new molecular/cellular analysis capabilities for cancer research (basic, clinical, epidemiology). Part of NCI’s IMAT program. Not for hypothesis-driven studies using existing tech.
Eligibility Criteria:
-
Organizations: higher-ed institutions, nonprofits, for-profits (incl. small businesses), government/tribal entities, and foreign organizations; foreign components allowed.
-
PD/PI must have an eRA Commons ID.
-
Multiple applications allowed if scientifically distinct.
-
Clinical trials are not allowed.
Funding Details:
-
Mechanism: R61 (exploratory/developmental).
-
Budget: up to USD 150,000 in direct costs per year, for up to 3 years.
Deadline:
-
Application due: October 3, 2025 (5:00 PM local time).
Where to Go for Further Information:
-
Scientific contact: Kelly Crotty, Ph.D. — [email protected]
-
General grants info: [email protected]